Seegene Inc., a South Korea-based molecular diagnostics company, previewed its upcoming CURECA™ system at ESCMID Global 2025 in Vienna. Presented via a concept video, the platform garnered strong attention for its potential to fully automate the PCR testing workflow—from sample handling to results analysis. Its Customizable Pre-treatment System (CPS) aims to automate specimen loading and processing across a wide range of diagnostic fields, eliminating manual steps prone to human error and delays.

Industry experts attending ESCMID highlighted the platform's promise in enhancing efficiency, especially in time-sensitive areas such as STI testing, where manual handling remains labor-intensive. Seegene's modular architecture allows labs to integrate only the components they need, including the CPS, the Primary Sample Aliquot System (PAS), or the CEFA framework for full automation. This tailored approach caters to varying lab sizes and layouts, making the system scalable and adaptable.

Seegene emphasized that CURECA™ is designed for unattended workflows, offering labs the flexibility to configure the system based on space, staffing, and testing demands. With launch plans slated for ADLM 2025 in Chicago, the company believes CURECA™ could reshape global PCR testing standards and streamline diagnostics for small and mid-sized labs worldwide.

MedTech Spectrum's Summary

• End-to-End PCR Automation: CURECA™ integrates all stages of PCR diagnostics, from pre-treatment to result interpretation, addressing a major gap in lab workflows.

• Flexible Modular System: With CPS, PAS, and CEFA modules, labs can build customized setups suited to their operations and spatial constraints.

• Improved Efficiency and Accuracy: Automated processes reduce operator fatigue, speed up testing, and minimize errors associated with manual specimen handling.